Efficacy of the addition of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: A multi-institutional, randomized, double-blinded, placebo-controlled trial (JORTC Pal 08 (trials in progress)
Management of cancer patients suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge. Duloxetine is one of the choices after first-line treatment fails. The efficacy…

